We are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.
Copyright Nasdaq. Minimum 15 minutes delayed.
4:30 PM EDT
|Second Quarter 2018 Financial Results|
8:00 AM EDT
|Akebia Therapeutics and Keryx Biopharmaceuticals Joint Corporate Conference Call|
4:00 PM EDT
|UBS Global Healthcare Conference|